Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model | Zendy

JosephA Davis | Zendy; PuchaS Kumar | Zendy; Shuchita Singh | Zendy; A. SURENDER | Zendy; Subhasis Roy | Zendy; Vivek Khanna | Zendy; Sachin Sethi | Zendy; Chanchan Pal | Zendy; Lalima Sharma | Zendy; Biju Benjamin | Zendy; Shivani Mittra | Zendy; Jitendra A. Sattigeri | Zendy; VinayS Bansal | Zendy

Open Access

Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model

Author(s) -

JosephA Davis,

PuchaS Kumar,

Shuchita Singh,

A. SURENDER,

Subhasis Roy,

Vivek Khanna,

Sachin Sethi,

Chanchan Pal,

Lalima Sharma,

Biju Benjamin,

Shivani Mittra,

Jitendra A. Sattigeri,

VinayS Bansal

Publication year - 2012

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.103298

Subject(s) - sitagliptin , dipeptidyl peptidase , incretin , potency , chemistry , in vivo , pharmacology , type 2 diabetes , proteases , vildagliptin , endocrinology , medicine , dipeptidyl peptidase 4 , enzyme , diabetes mellitus , in vitro , biochemistry , biology , microbiology and biotechnology

Dipeptidyl peptidase IV (DPP-IV) inhibition to modulate the incretin effect is a proven strategy to treat type 2 diabetes mellitus. The present study describes the pharmacological profile of a novel DPP-IV inhibitor RBx-0128, as an antidiabetic agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research